MFDS Announces Partial Amendment to the Medical Devices Act Enforcement Rule
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi1lPJBvVKGM_uiEar60G-zJEjFsbEviJV73N-lCr2jAKvFiEfn4VC2KbUmfVxXYim2cJwM4M0J_7Y476qG-iIZC0OYfU_CWbUu-AUgppSXbJNUR3sgeTTpYiL4XE1pXUibGa2SUp4GRojPEyd6Kif0-85-3WlSdxeZ0n2h1mzoESzUBa4iw5pYCfCusuyp/w363-h251/%EC%9D%98%EB%A3%8C%EA%B8%B0%EA%B8%B0.png)
Medical Devices (MFDS) The Ministry of Food and Drug Safety (MFDS) has announced a partial amendment to the Enforcement Rule of the Medical Devices Act. Public opinions will be collected until July 23, 2024. • The basis for the disclosure of comprehensive plans and implementation plans for medical device safety management will be established. • The reporting procedure will be clarified to allow the manufacturing and import of low-risk Class I medical devices through manufacturing and import notification only. • To clarify the medical device notification acceptance procedure, the acceptance period will be set to 5 days, matching the Class II certification period, and a new form for the notification acceptance certificate (including conditional certificates) will be established. • Clinical trials with minimal risk to participants will be exempt from clinical trial plan approval. • Clinical trials that non-clinical trial institutions can participate in will be defined, and guidelines f